MOTS-c: from exercise-mimetic science to the FDA's compounding committee
Last updated: November 4, 2026 · 5 min read · By the Grey Peptides Editorial Board
- MOTS-c is a 16-amino-acid peptide coded not in the cell's nucleus but in mitochondrial DNA. In mice it improves how muscle handles glucose and boosts physical capacity, which is where the "exercise mimetic" label comes from.
- The human studies measure only the body's own MOTS-c: a genetic variant linked to diabetes, levels that rise with exercise or heat. No published trial has given MOTS-c to people and measured what it does.
- In July 2026 the FDA's compounding committee voted 7 to 5 to recommend it for the 503A list, against its scientists' advice, as a law firm reported the vote; at our October 27 check it was not on the FDA's list. WADA bans it by name in S4.4.1.
A peptide from mitochondrial DNA
MOTS-c Low was named in 2015, when researchers found that a short stretch inside the mitochondrial 12S rRNA gene encodes a 16-amino-acid peptide. In mice it regulated insulin sensitivity and metabolic balance, and its main target appeared to be skeletal muscle, and it inhibited the folate cycle in a way that switched on AMPK, the cell's energy sensor 1. Under metabolic stress it moved into the cell nucleus in an AMPK-dependent way and changed the activity of genes that respond to glucose restriction and oxidative stress 2. Its levels in plasma fall with age, according to a 2023 review 3.
Researchers themselves call it an "exercise-mimetic peptide" 4 with "exercise mimetic activity" 5, on the strength of these mouse findings. The phrase describes a mechanism seen in mice, not an effect shown in people.
What the animal studies show
One study treated mice of three ages, 2, 12 and 22 months, and found MOTS-c significantly improved physical performance in all of them; intermittent treatment three times a week started at 23.5 months increased physical capacity and what the authors called healthspan 6. In another, mice with one leg immobilised for eight days lost about 15% of muscle mass, but only about 5% when given MOTS-c daily at 15 mg/kg 7. No study has tested these doses or schedules in people.
What is known in people
Every human study so far has measured the body's own MOTS-c; none has given it. A variant of mitochondrial DNA that the authors describe as Asian-specific, m.1382A>C, changes one amino acid of MOTS-c; in three cohorts totalling 27,527 people, men carrying it had more type 2 diabetes, but women did not 8. In a randomised trial of exercise in breast-cancer survivors, MOTS-c levels rose after 16 weeks of training among the 24 non-Hispanic White participants but not among the 25 Hispanic participants 5. In the mouse-ageing study above, exercise also raised MOTS-c in human muscle and blood 6. In 19 active men randomised to heat or sham treatment while an ankle was immobilised for two weeks, heat raised circulating MOTS-c 9. And because metformin shares much of its mechanism, researchers checked whether metformin raised MOTS-c in women with breast cancer; it did not 4.
What is missing is the study that matters: a PubMed search on October 27, 2026 found no published trial in which people were given MOTS-c and its effect on muscle, glucose or weight was measured, so no dose of it has been tested in people.
The 2026 compounding committee vote
MOTS-c was one of seven peptides the FDA's Pharmacy Compounding Advisory Committee considered on July 23 and 24, 2026, for the list of substances pharmacies may compound under section 503A. FDA's meeting page lists the uses it reviewed, for MOTS-c obesity and osteoporosis 10. According to a law firm's summary, FDA scientists recommended against including each of the seven, "citing concerns of insufficient safety", efficacy and characterisation information, and the committee voted 7 to 5 with two abstentions to recommend MOTS-c anyway; FDA has posted no tallies 11 10.
A committee vote is advice the FDA can accept or reject, and adding a substance to the list takes rulemaking 11. At our check on October 27, 2026, MOTS-c was not in Category 1 of the FDA's 503A list (updated May 14, 2026), so the legal position for pharmacies was unchanged 10. Our PCAC page follows all seven.
On October 30, 2026, HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of MOTS-c under the forms, routes and conditions in its Appendix B 12. The policy is non-binding, labelled a draft and open to revision; FDA has not added it to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales (our fact check).
Why it is banned in sport
WADA's 2026 Prohibited List names MOTS-c, written out as the mitochondrial open reading frame of the 12S rRNA-c, as an activator of AMPK under S4.4.1, alongside AICAR 13. It is therefore prohibited at all times. A ban based on a mechanism is not evidence that it enhances performance in humans; it reflects the mouse data and the class it belongs to.
Frequently asked questions
Is MOTS-c an exercise mimetic?
In mice it improves glucose handling in muscle and physical capacity through AMPK-linked pathways, which is why it is called one. No published trial has tested that in people.
Has MOTS-c been tested in humans?
Only the body's own MOTS-c has been measured: a genetic variant linked to diabetes in men, and levels that rise with exercise or heat. A PubMed search on October 27, 2026 found no published trial of MOTS-c given to people.
Is MOTS-c legal to compound?
The FDA's compounding committee voted 7 to 5 in July 2026 to recommend it for the 503A list, against FDA scientists' advice, according to a law firm's summary. At our check on October 27, 2026, it was not on the FDA's list.
Is MOTS-c banned by WADA?
Yes. The 2026 Prohibited List names it under S4.4.1 as an AMPK activator, prohibited at all times.
Related on Grey Peptides
Sources
- Lee, C., et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab, 21(3), 443-54. PMID: 25738459
- Kim, K. H., et al. (2018). The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab, 28(3), 516-524.e7. PMID: 29983246
- Zheng, Y., et al. (2023). MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol (Lausanne), 14, 1120533. PMID: 36761202
- Cuyàs, E., et al. (2022). Circulating levels of MOTS-c in patients with breast cancer treated with metformin. Aging (Albany NY), 15(4), 892-897. PMID: 36490309
- Dieli-Conwright, C. M., et al. (2021). Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Sci Rep, 11(1), 16916. PMID: 34413391
- Reynolds, J. C., et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun, 12(1), 470. PMID: 33473109
- Kumagai, H., et al. (2024). Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration. Am J Physiol Endocrinol Metab, 326(3), E207-E214. PMID: 38170165
- Zempo, H., et al. (2021). A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY), 13(2), 1692-1717. PMID: 33468709
- Elhusseiny, R., et al. (2025). Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization. Med Sci Sports Exerc, 57(12), 2764-2774. PMID: 40674654
- US FDA. Pharmacy Compounding Advisory Committee, July 23-24, 2026 meeting: uses reviewed and briefing documents; no minutes or vote tallies posted (content current as of August 6, 2026); 503A list (updated May 14, 2026) re-read October 27, 2026: none of the six recommended peptides in Category 1. FDA
- McDermott (law firm). Bulk-list bound? PCAC backs majority of peptides in two-day public meeting (July 27, 2026): tallies for all seven. Read October 27, 2026; FDA has posted no minutes or tallies. Other reports agree on every tally except epitalon's 'no' count (7-4-1 here and in the FDA Law Blog; 7-5-1 in RAPS Regulatory Focus). Cited without a link.
- US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register
- World Anti-Doping Agency. Prohibited List 2026, section S4.4.1 (AMPK activators: AICAR, BAM15, MOTS-c); in effect January 1, 2026; re-read October 27, 2026. WADA
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead